Dan Teleman, CEO of Pharma Two B, added, “These data provide further support for P2B001 as a first-line, once-daily combination pill treatment for people with early PD that requires no titration.

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 ...

GREENVILLE, N.C (WNCT) — The pharmaceutical industry is rapidly growing right here in the east, and events like today’s Spring Pharma Conference at ECU emphasize that. A two-day conference at ...

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of ...

DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice ...

SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announcedthat the company will present three ...

News GlobeNewswire aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference ...

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference aTyr Pharma, Inc. - GlobeNewswire - Mon May 19, 7:00AM CDT ...